HIV vaccine trial willingness among injection and non-injection drug users in two urban centres, Barcelona and San Francisco

Being able to recruit high-risk volunteers who are also willing to consider future participation in vaccine trials are critical features of vaccine preparedness studies. We described data from two cohorts of injection- and non-injection drug users in Barcelona, Spain [Red Cross centre] and in San Fr...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2011-02, Vol.29 (10), p.1991-1996
Main Authors: Etcheverry, M. Florencia, Lum, Paula J, Evans, Jennifer L, Sanchez, Emilia, de Lazzari, Elisa, Mendez-Arancibia, Eva, Sierra, Ernesto, Gatell, José M, Page, Kimberly, Joseph, Joan
Format: Article
Language:English
Subjects:
Acquired immune deficiency syndrome
Adult
AIDS
AIDS Vaccines - immunology
Allergy and Immunology
Applied microbiology
Biological and medical sciences
Clinical Trials as Topic
Drug use
Drug Users
Female
Fundamental and applied biological sciences. Psychology
Hepatitis C virus
HIV
HIV vaccines
Human immunodeficiency virus
Humans
IDUs
Injection
Injection and non-injection drug users
Male
Microbiology
Miscellaneous
Patient Acceptance of Health Care - statistics & numerical data
risk
risk behavior
Risk taking
San Francisco
screening
seroprevalence
Spain
Studies
Substance Abuse, Intravenous
Vaccines
Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)
Virology
volunteers
Willingness to participate in future trials
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Being able to recruit high-risk volunteers who are also willing to consider future participation in vaccine trials are critical features of vaccine preparedness studies. We described data from two cohorts of injection- and non-injection drug users in Barcelona, Spain [Red Cross centre] and in San Francisco, USA, [UFO-VAX study] at high risk of HIV/HCV infection to assess behaviour risk exposure and willingness to participate in future preventive HIV vaccine trials. We successfully identified drug-using populations that would be eligible for future HIV vaccine efficacy trials, based on reported levels of risk during screening and high levels of willingness to participate. In both groups, Red Cross and UFO-VAX respectively, HCV infection was highly prevalent at baseline (41% and 34%), HIV baseline seroprevalence was 4.2% and 1.5%, and high levels of willingness were seen (83% and 78%).
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2010.12.043